Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"

Takeda

Status: Completed

Conditions: Parkinson's Disease

Treatments: Drug: Rasagiline

Study type: Observational

Funder types: Industry

Identifiers

NCT03727139

JapicCTI-184181 (Registry Identifier)

Rasagiline-5001

Details and patient eligibility

About

The purpose of this survey is to evaluate the long-term safety of Rasagiline (AZILECT) in patients with Parkinson's disease in daily clinical practice and also collect efficacy information.

Full description

The drug being tested in this survey is called rasagiline tablet. This tablet is being tested to treat people with Parkinson's disease.

This survey is an observational (non-interventional) study and will look at the long-term safety and efficacy of the rasagiline tablet in the routine clinical setting. The planned number of observed patients will be approximately 1000.

This multi-center observational trial will be conducted in Japan.

Enrollment: 1,021 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients with Parkinson's disease should be surveyed.

Exclusion criteria

-Participants who have contraindications on package insert of rasagiline.

Trial design

1,021 participants in 1 patient group

Rasagiline 1 mg

Description:

Rasagiline 1 milligram (mg), orally, once daily for up to 24 months. Participants received interventions as part of routine medical care.

Treatment:

Drug: Rasagiline